唑来膦酸治疗既往用过双膦酸盐的实体瘤骨痛的疗效观察

Therapeutic effect of zoledronic acid for pain palliation in patients with solid tumor who previously received bisphosphonate therapy

目的评价唑来膦酸治疗既往用过双膦酸盐的实体瘤骨转移患者骨疼痛的缓解效果和安全性。方法唑来膦酸4mg静脉注射>15min,1次/4周,治疗既往用过和未用过双膦酸盐的骨转移实体瘤患者,记录疼痛评分,东方协作肿瘤组织(ECOG)体力状态评分和不良反应,每次用药前检测血肌酐水平。结果疼痛评分较基线下降,ECOG体力状态评分保持稳定。51例患者中,既往用过双膦酸盐28例(54.9%)。发热、乏力和恶心是最常见的不良反应,血清肌酐值无明显升高,在既往用过与未用过双膦酸盐患者间不良反应发生率无统计学意义。结论既往用过双膦酸盐静脉注射治疗的实体瘤骨转移患者,可安全的给予唑来膦酸治疗。

Objective To evaluate the safety and pain palliation effects of zoletdronic acid in patients with solid tumor who previously received bisphosphonate therapy. Methods Zoledronic acid 4 mg intravenously over 15 minutes every 4 weeks as treatment of hone metastases in patients with solid tumor with and without previous bisphosphonate exposure. Pain score, eastern Cooperative Oncology Group（ECOG） performance status scores and adverse events （AEs） were recorded, and scrum creatinine （SCr） levels were measured before each infusion. Results Pain scores decreased front baseline （P 〈 0. 001 ） ; ECOG performance status scores remained constant （ P 〉 0.05 ）. Of 51 patients, 28 patients （54.9 % ） had received prior bisphosphonate therapy. Pyrexia, fatigue, and nausea were the most frequent AEs. SCr level was not increased notably. There was no significant difference observed between the two groups（ P 〉 0.05）. Conclusion Solid tumor patients with bone metastases who have previously received intravenous bisphosphonate treatment can be safely converted to zoledronic acid therapy.